(CNDX) NASDAQ 100 USD - Overview
Etf: Technology, Consumer, Communication, Healthcare, Industrial
| Risk 5d forecast | |
|---|---|
| Volatility | 20.8% |
| Relative Tail Risk | 1.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.01 |
| Alpha | -6.69 |
| Character TTM | |
|---|---|
| Beta | 0.297 |
| Beta Downside | 0.464 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.57% |
| CAGR/Max DD | 0.91 |
Description: CNDX NASDAQ 100 USD December 19, 2025
The iShares NASDAQ 100 UCITS ETF USD (Acc) (ticker CNDX) is a Netherlands-registered exchange-traded fund that tracks the Morningstar US Large-Cap Growth NR USD index, providing exposure to the 100 largest non-financial U.S. companies by market capitalisation.
Key quantitative attributes (as of Q4 2024) include an expense ratio of 0.33 %, assets under management of roughly $12 billion, and a 12-month trailing return of +18 % (annualised). The fund’s top holdings remain heavily weighted toward mega-cap technology firms-Apple, Microsoft and Amazon together represent about 35 % of net assets-while the sector breakdown is roughly 55 % technology, 20 % consumer discretionary, and the remainder split among health-care, communication services and industrials. Performance is therefore closely tied to U.S. tech earnings growth and the Federal Reserve’s monetary stance, which influences valuation multiples for high-growth stocks.
If you want a deeper, data-driven view of how CNDX fits into a broader portfolio framework, a quick look at ValueRay’s analytics can help you surface the most relevant risk-adjusted metrics.
What is the price of CNDX shares?
Over the past week, the price has changed by -2.35%, over one month by -3.31%, over three months by -3.15% and over the past year by +1.24%.
Is CNDX a buy, sell or hold?
What are the forecasts/targets for the CNDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1420.5 | 17.3% |
CNDX Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 22.16b EUR (22.16b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 22.16b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 22.16b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.01% (E(22.16b)/V(22.16b) * Re(7.01%) + (debt-free company))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)